For October 2018, we have selected two papers. The first is: Adams D, Gonzales-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.(APOLLO trial). NEJM 2018;179:11-21. The second is: Benson MD, M Waddington-Cruz, JL Berk, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. (NEURO-TTR trial) NEJM 2018;179:22-31. Hereditary transthyretin amyloidosis is a rare autosomal dominant disorder in which mutations of the gene for transthyretin protein (TTR) induce systemic deposition of amyloid.

European Huntingston's Disease Network Plenary Network 2018 16th PAUNS congress (Pan-Arab Union of Neurological Societies) Basic & Advanced Neuromuscular Ultrasound Course 8th Annual Brain Metastases Research and Emerging Therapy Conference 24th Congress of the European Sleep Research Society EXCEMED practice teaching course: In-depth MRI techniques and analysis in multiple sclerosis

Basic and Advanced Neuromuscular Ultrasound Course September 19th – 22nd 2018, Dubai, United Arab Emirates This course is concentrated on learning of the normal neuromuscular ultrasound anatomy of the upper and lower extremities and obtaining basic practical skills on neuromuscular… Continue Reading